Study of association and prognostic correlation of cardiac troponin I estimation in acute decompensated heart failure patients
DOI:
https://doi.org/10.18203/2349-3933.ijam20205403Keywords:
Acute decompensated heart failure, Biomarkers, Troponins, PrognosisAbstract
Background: Heart failure is a major public health problem since last few decades affecting significant number of people worldwide. Acute decompensated heart failure is a major cause of hospitalization in elderly people with a high mortality rate. Heterogeneity and non-specificity of symptoms makes diagnosis of heart failure by clinical presentation alone more challenging. Aim of current study was to investigate troponin biomarkers in diagnosis, prognosis and management of acute decompensated heart failure.
Methods: Present study was a prospective observational study conducted on 100 patients at Department of Cardiology, Superspeciality hospital, NSCB medical college Jabalpur and Department of cardiology Superspeciality hospital, SS medical college Rewa from October 2019 to August 2020. Patients were investigated for clinical, echocardiographic parameters and NYHA classification. Cardiac functions were analyzed by color doppler echocardiography.
Results: According to study findings, 65.2% of TnI positive patients were males whereas 34.8% were females. Mean age of TnI positive group was observed to be higher. Majority of troponin positive patients were in NYHA class IV. Recurrent hospitalization was observed more in TnI positive group. Logistic regression analysis depicted systolic blood pressure reduced significantly (p<0.001) on follow up study in TnI positive patients, FBS was significantly more in TnI positive patients (131.4+42.9 mg/dl) (p=0.049). LVID was significantly more in TnI positive patients (p=0.022). Reduction in EF was statistically significant (p=0.03) at the three months follow up study.
Conclusions: A positive prognostic correlation was established between ADHF and troponin positivity, large prospective randomized trials are necessary to recommend quantitative troponin I determination in all patients of acute decompensated heart failure for prognosis and guiding therapy.
Metrics
References
Allen LA, Yager JE, Funk MJ, Levy WC, Tulsky JA, Bowers MT, et al. Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. J Am Med Assoc. 2008;299(21):2533-42.
Arena R, Myers J, Williams MA, Gulati M, Kligfield P, Balady GJ, et al. Assessment of functional capacity in clinical and research settings: a scientific statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention of the Council on Clinical Cardiology and the Council on Cardiovascular Nursing. Circulation. 2007;116(3):329-43.
Joseph SM, Cedars AM, Ewald GA, Geltman EM, Mann DL. Acute decompensated heart failure: contemporary medical management. Tex Heart Inst J. 2009;36(6):510-20.
Reddy YNV, Melenovsky V, Redfield MM, Nishimura RA, Borlaug BA. High-Output Heart Failure: A 15-Year Experience. J Am Coll Cardiol. 2016;68(5):473-82.
Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3(1):7-11.
Ponikowski P, Anker SD, Al Habib KF. Heart failure: preventing disease and death worldwide. ESC Heart Failure. 2014;1:4-25.
Mozaffarian D, Benjamin EJ, Go AS. American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A report from the American Heart Association. Circulation. 2016;133:e38-60.
Gomez-Soto FM, Andrey JL, Garcia-Egido AA. Incidence and mortality of heart failure: a community-based study. Int J Cardiol. 2011;151:40-5.
Seth S, Khanal S, Ramakrishnan S, Gupta N, Bahl VK. Epidemiology of acute decompensated heart failure in India: The AFAR study (Acute failure registry study). J Pract Cardiovasc Sci. 2015;1:35-8.
10. Huffman MD, Prabhakaran D. Heart failure: Epidemiology and prevention in India. Natl Med J India. 2010;23:283-8.
Pillai HS, Ganapathi S. Heart failure in South Asia. Curr Cardiol Rev. 2013;9:102-11.
Harikrishnan S, Sanjay G, Anees T, Viswanathan S, Vijayaraghavan G, Bahuleyan CG, et al. Clinical presentation, management, in-hospital and 90-day outcomes of heart failure patients in Trivandrum, Kerala, India: The Trivandrum Heart Failure Registry. Eur J Heart Fail. 2015;17:794-800.
Braunwald E, Harrison DC, Chidsey CA. The heart as an endocrine organ. Am J Med. 1964;36:1-4.
Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358(20):2148-59.
Paul S, Harshaw-Ellis K. Evolving use of biomarkers in the manage-ment of heart failure. Cardiol Rev. 2019;27:153-9.
Sarhene M, Wang Y, Wei J, Huang Y, Li M, Li L, et al. Biomarkers in heart failure: the past, current and future. Heart Fail Rev. 2019;24(6):867-903.
Squire IB. Biomarkers and prognostication in heart failure with re-duced and preserved ejection fraction: similar but different?. Eur J Heart Fail. 2017;19:1648-50.
Nadar SK, Shaikh MM. Biomarkers in routine heart failure clinicalcare. Card Fail Rev J. 2019;5:1-7.
Ibrahim NE, Januzzi JL. Beyond natriuretic peptides for diagnosis and management of heart failure. Clin Chem. 2017;63:211-22.
Nadar SK, Shaikh MM. Biomarkers in routine heart failure clinical care. Card Fail Rev. 2019;5(1):50-6.
Xue Y, Clopton P, Peacock WF, Maisel AS. Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. Eur J Heart Fail. 2011;13:37-42.
Daubert MA, Jeremias A. The utility of troponin measurement to detect myocardial infarction: review of the current findings. Vasc Health Risk Manag. 2010;6:691-9.
Sharma S, Jackson PG, Makan J. Cardiac troponins. J Clin Pathol. 2004;57(10):1025-6.
Peacock WF, Baumann BM, Bruton D. Efficacy of high-sensitivity troponin T in identifying very-low-risk patients with possible acute coronary syndrome. J Am Med Assoc Cardiol. 2018;3(2):104-11.
Westermann D, Neumann JT, Sörensen NA, Blankenberg S. High-sensitivity assays for troponin in patients with cardiac disease. Nat Rev Cardiol. 2017;14(8):472-83.
Figg P. Soluble ST2, high sensitivity troponin T and N terminal, Complementary role in risk stratification in ADHF. Eur J Heart Fail. 2011;13:718-25.
Miller WL, Hartman KA, Burritt MF, Grill DE, Rodeheffer RJ, Burnett JC, et al. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation. 2007;116(3):249-57.
Perna ER, Macin SM, Canella JP, Augier N, Stival JL, Cialzeta JR, et al. Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification. Circulation. 2004;110(16):2376-82.
Kocial S, Seino Y. Clinical significance of elevated levels of cardiac Troponin T in patients with chronic heart failure. Am J Cardiol. 1990;84;608-11.
Latini R. Troponins in Heart failure. Res Esp Cardiol. 2008;61(7);667-9.
Del Carlo CH, Pereira-Barretto AC, Cassaro-Strunz C, Latorre Mdo R, Ramires JA. Serial measure of cardiac troponin T levels for prediction of clinical events in decompensated heart failure. J Card Fail. 2004;10(1):43-8.
Siirilä-Waris K, Lassus J, Melin J, Peuhkurinen K, Nieminen MS, FINN-AKVA study group, et al. Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J. 2006;27(24):3011-7.
Pascual-Figal DA, Manzano-Fernández S, Boronat M, Casas T, Garrido IP, Bonaque JC, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail. 2011;13(7):718-25.
Hudson MP, O'Connor CM, Gattis WA, Tasissa G, Hasselblad V, Holleman CM, et al. Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. Am Heart J. 2004;147(3):546-52.
Downloads
Published
How to Cite
Issue
Section
